Nat Commun:VHL缺陷通过下调ALDH2增强透明细胞肾细胞癌的蒽环霉素敏感性

2017-06-15 MedSci MedSci原创

肾细胞癌是肾肿瘤中最常见的一种类型。众所周知,RCC对常规化学治疗有抵抗性,大多数病人在化学治疗中饱受副作用之苦,肾肿瘤的药物治疗依然不甚理想。因而,目前急需鉴别针对RCC的潜在治疗靶点和化学药剂。

肾细胞癌是肾肿瘤中最常见的一种类型。众所周知,RCC对常规化学治疗有抵抗性,大多数病人在化学治疗中饱受副作用之苦,肾肿瘤的药物治疗依然不甚理想。因而,目前急需鉴别针对RCC的潜在治疗靶点和化学药剂。

70%的透明细胞肾细胞癌(ccRCC)中出现VHL缺陷,这一缺陷导致肿瘤以及ccRCC的药物抵抗。近日一项发表在Nature communication上的研究显示,蒽环霉素对VHL-缺陷的ccRCC细胞具有较强的细胞毒性,这种作用以一种不依赖于低氧诱导因子(HIF)的方式发生。

此研究中,通过消减蛋白质组分析结合RNA干扰以及过表达证明等手段发现,乙醛脱氢酶2(ALDH2)被VHL转录性地调节,这种调节导致蒽环霉素在VHL-缺陷的ccRCC细胞上毒性增强。而且,VHL直接结合到ALDH2的130bp-160bp启动子上活化肝细胞核因子4α(HNF-4α)转录,调节ALDH2表达。此外,在对ccRCC样品的研究中发现,VHL、HNF-4α和ALDH2蛋白表达之间存在正向相关。

总结来看,这项研究发现VHL-缺陷下调ccRCC中ALDH2,从而增强蒽环霉素的化学疗效。这项工作加深了对VHL功能的理解,并为以后针对ccRCC病人的精准治疗提供思路。

原始出处:
Yao-Hui Gao, Zhao-Xia Wu, Li-Qi Xie, et al. VHL deficiency augments anthracycline sensitivity of clear cell renal cell carcinomas by down-regulating ALDH2. Nat commun. 2017 Jun 15. doi: 10.1038/ncomms15337

版权声明:本文系梅斯MedSci原创编译整理,未经本网站授权不得转载和使用。如需获取授权,请点击

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1700294, encodeId=14711e0029413, content=<a href='/topic/show?id=bb151841e20' target=_blank style='color:#2F92EE;'>#VHL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18417, encryptionId=bb151841e20, topicName=VHL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1630038802, createdName=Eleven21, createdTime=Sat Feb 03 05:26:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087064, encodeId=f5f3208e0649d, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Mar 07 20:26:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882177, encodeId=eb6518821e773, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Aug 01 12:26:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978510, encodeId=3cf719e8510aa, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sat Oct 14 22:26:00 CST 2017, time=2017-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388359, encodeId=d96d13883593a, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Sat Jun 17 13:26:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469395, encodeId=324b14693955a, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2276, encryptionId=9d6522e613, topicName=ALD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64f67025397, createdName=zhangjingnwpu, createdTime=Sat Jun 17 13:26:00 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
    2018-02-03 Eleven21
  2. [GetPortalCommentsPageByObjectIdResponse(id=1700294, encodeId=14711e0029413, content=<a href='/topic/show?id=bb151841e20' target=_blank style='color:#2F92EE;'>#VHL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18417, encryptionId=bb151841e20, topicName=VHL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1630038802, createdName=Eleven21, createdTime=Sat Feb 03 05:26:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087064, encodeId=f5f3208e0649d, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Mar 07 20:26:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882177, encodeId=eb6518821e773, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Aug 01 12:26:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978510, encodeId=3cf719e8510aa, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sat Oct 14 22:26:00 CST 2017, time=2017-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388359, encodeId=d96d13883593a, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Sat Jun 17 13:26:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469395, encodeId=324b14693955a, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2276, encryptionId=9d6522e613, topicName=ALD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64f67025397, createdName=zhangjingnwpu, createdTime=Sat Jun 17 13:26:00 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
    2018-03-07 liuli5079
  3. [GetPortalCommentsPageByObjectIdResponse(id=1700294, encodeId=14711e0029413, content=<a href='/topic/show?id=bb151841e20' target=_blank style='color:#2F92EE;'>#VHL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18417, encryptionId=bb151841e20, topicName=VHL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1630038802, createdName=Eleven21, createdTime=Sat Feb 03 05:26:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087064, encodeId=f5f3208e0649d, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Mar 07 20:26:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882177, encodeId=eb6518821e773, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Aug 01 12:26:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978510, encodeId=3cf719e8510aa, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sat Oct 14 22:26:00 CST 2017, time=2017-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388359, encodeId=d96d13883593a, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Sat Jun 17 13:26:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469395, encodeId=324b14693955a, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2276, encryptionId=9d6522e613, topicName=ALD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64f67025397, createdName=zhangjingnwpu, createdTime=Sat Jun 17 13:26:00 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
    2017-08-01 liye789132251
  4. [GetPortalCommentsPageByObjectIdResponse(id=1700294, encodeId=14711e0029413, content=<a href='/topic/show?id=bb151841e20' target=_blank style='color:#2F92EE;'>#VHL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18417, encryptionId=bb151841e20, topicName=VHL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1630038802, createdName=Eleven21, createdTime=Sat Feb 03 05:26:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087064, encodeId=f5f3208e0649d, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Mar 07 20:26:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882177, encodeId=eb6518821e773, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Aug 01 12:26:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978510, encodeId=3cf719e8510aa, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sat Oct 14 22:26:00 CST 2017, time=2017-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388359, encodeId=d96d13883593a, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Sat Jun 17 13:26:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469395, encodeId=324b14693955a, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2276, encryptionId=9d6522e613, topicName=ALD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64f67025397, createdName=zhangjingnwpu, createdTime=Sat Jun 17 13:26:00 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1700294, encodeId=14711e0029413, content=<a href='/topic/show?id=bb151841e20' target=_blank style='color:#2F92EE;'>#VHL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18417, encryptionId=bb151841e20, topicName=VHL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1630038802, createdName=Eleven21, createdTime=Sat Feb 03 05:26:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087064, encodeId=f5f3208e0649d, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Mar 07 20:26:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882177, encodeId=eb6518821e773, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Aug 01 12:26:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978510, encodeId=3cf719e8510aa, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sat Oct 14 22:26:00 CST 2017, time=2017-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388359, encodeId=d96d13883593a, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Sat Jun 17 13:26:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469395, encodeId=324b14693955a, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2276, encryptionId=9d6522e613, topicName=ALD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64f67025397, createdName=zhangjingnwpu, createdTime=Sat Jun 17 13:26:00 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1700294, encodeId=14711e0029413, content=<a href='/topic/show?id=bb151841e20' target=_blank style='color:#2F92EE;'>#VHL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18417, encryptionId=bb151841e20, topicName=VHL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3f1630038802, createdName=Eleven21, createdTime=Sat Feb 03 05:26:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087064, encodeId=f5f3208e0649d, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Wed Mar 07 20:26:00 CST 2018, time=2018-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1882177, encodeId=eb6518821e773, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Aug 01 12:26:00 CST 2017, time=2017-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978510, encodeId=3cf719e8510aa, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sat Oct 14 22:26:00 CST 2017, time=2017-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1388359, encodeId=d96d13883593a, content=<a href='/topic/show?id=7ef25e5346b' target=_blank style='color:#2F92EE;'>#敏感性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=57534, encryptionId=7ef25e5346b, topicName=敏感性)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJnkE6UvGFfMS41qV0RicWvVTTeLMicqibeZH5GqO4YhNicyl1Y9jFhylIUBn9ntPYy9jhk5hrfic5cRYw/132, createdBy=5f822500020, createdName=ms5236388012055669, createdTime=Sat Jun 17 13:26:00 CST 2017, time=2017-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469395, encodeId=324b14693955a, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2276, encryptionId=9d6522e613, topicName=ALD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64f67025397, createdName=zhangjingnwpu, createdTime=Sat Jun 17 13:26:00 CST 2017, time=2017-06-17, status=1, ipAttribution=)]
    2017-06-17 zhangjingnwpu

相关资讯

MotleyFool评选:2016年医药领域年度12大突破性进展

2016年结束了,让我们来回顾一下这一年中医疗保健行业都取得了哪些成就。美国食品和药物管理局(FDA)在2016年通过了19种新药的审核,这些新药的治疗疾病范围从银屑病到丙型肝炎再到癌症。与此同时,监管机构在2016年也为25种新型医疗设备亮了绿灯。全球每年投入研发的资金达数百亿美元,因此在看到投入的资金带来了这些可以改善我们的生命健康的药物和设备时,也倍感欣慰。 当然,也有一些非常吸睛

双重免疫治疗显神通,肾细胞癌有望获全新一线疗法

日前,罗氏集团公司基因泰克宣布了一项2期临床试验的最新数据。在这项试验中,TECENTRIQ®(atezolizumab)与Avastin®(bevacizumab)的联合疗法显著延长了初治晚期或转移性肾细胞患者的无进展生存期。此项免疫组合疗法也有望成为治疗肾细胞癌的全新一线疗法。

诺华药物依维莫司通过英国重新审查,作为二线药物治疗肾细胞癌

英国国家健康和护理研究所废除了此前关于依维莫司的规定,将推荐该药物作为治疗肾肿瘤的常规药物。此前由于英国启动NICE2011方案重新评估所有癌症药物基金支持的治疗方案,依维莫司只有在通过该方案审查后才可以使用。 而现在由于诺华提供了新的证据,NICE批准将该药物作为晚期肾细胞癌(RCC)的二线治疗药物。NICE卫生技术评估中心主任Carole Longson教授说道:“肾细胞癌是一种相对罕见的癌

Nat commun:MYC的激活与Vhl和Ink4a/Arf 功能的丢失可以诱导透明细胞肾细胞癌

肾癌是一种常见的并且具有侵入性的恶性肿瘤,并且该病的组织病理学并没有被人们完全理解。大多肾癌对细胞毒药物治疗具有抗性。最近,有研究人员利用两个肾癌小鼠模型来表述在人类乳头状肾细胞癌(pRCC)和透明细胞肾细胞癌(ccRCC), 这两种是最为常见的肾细胞癌亚型。研究发现,MYC激活导致高度渗透的乳头状肾细胞癌肿瘤(MYC),然而,当MYC激活与Vhl 和 Cdkn2a(Ink4a/Arf) 缺失 (

NEJM:舒尼替尼可显著延长高危肾细胞癌患者肾切除术后的无病生存期

舒尼替尼(一种血管内皮生长因子通路抑制剂)是转移性肾细胞癌的有效治疗方法。 该研究试图确定舒尼替尼对于肾脏切除术后肿瘤复发高风险的局部肾细胞癌患者的疗效和安全性。

卫材新型抗癌药lenvatinib一线治疗晚期肾细胞癌(RCC)进入III期临床开发

日本药企卫材(Eisai)近日宣布启动一项全球性的III期临床研究(Study 307,CLEAR),调查其内部开发的多受体酪氨酸激酶抑制剂lenvatinib分别联合诺华抗癌药 Afinitor(通用名:everolimus,依维莫司)及默沙东PD-1免疫疗法Keytruda(pembrolizumab)一线治疗晚期肾细胞癌(RCC)的潜力。 CLEAR研究是一项多中心、随机、开放标签II